Fosun Pharma Acquires Greater China Rights to Junshi Biosciences' Psoriasis Treatment, Roconkibart
1. Strategic Partnership to Target the Greater China Psoriasis Market
Fosun Wanbang Pharmaceutical, a subsidiary of Fosun Pharma, has partnered with Junshi Biosciences to make a significant move into the Greater China psoriasis market. Through this agreement, Fosun Wanbang Pharmaceutical secures exclusive development and commercialization rights for Roconkibart (JS005), Junshi Biosciences' innovative anti-IL-17A monoclonal antibody, within the Greater China region. The deal, valued at up to 1.335 billion yuan (approximately $198 million), including an upfront payment of 215 million yuan (approximately $32 million), demonstrates Fosun Pharma's commitment to strengthening its autoimmune disease portfolio. Furthermore, the agreement includes provisions for tiered royalties based on net sales upon successful commercialization, establishing a foundation for long-term collaboration between the two companies.
2. Minimizing Commercialization Risk with Approaching Regulatory Approval
Roconkibart, the subject of this transaction, is a promising asset that has already reached the final stages of clinical development, minimizing the risk of commercialization failure. Junshi Biosciences submitted a New Drug Application (NDA) to the China National Medical Products Administration (NMPA) in December of last year for moderate-to-severe plaque psoriasis. In Phase 3 clinical trials, Roconkibart demonstrated remarkable efficacy, with 91% of patients achieving PASI 90 (a 90% improvement in the Psoriasis Area and Severity Index) at week 16. Moreover, at week 52, 65% of patients achieved PASI 100, indicating complete clearance of skin lesions, further demonstrating its potential for long-term maintenance therapy.
3. Intensifying Competition in China's IL-17A Targeted Therapy Market
The psoriasis treatment market in China is currently characterized by intense competition among global pharmaceutical giants and local biotech companies. Following the 2019 approval of Novartis' Cosentyx, other major players such as Eli Lilly's Taltz and UCB's Bimzelx have entered the market. Recently, innovative drugs from local companies, such as Akeso's Gumokimab, have also been approved, and CSPC has joined the fray with a biosimilar of Cosentyx. Livzon Pharmaceutical's Lecankitug has also demonstrated superiority over Cosentyx in clinical trials and is undergoing regulatory review, suggesting that securing market share will be challenging.
4. A Win-Win Strategy Leveraging Fosun's Distribution Network and Junshi's Funding
Amidst this intense competition, the partnership between Fosun and Junshi is viewed as a smart "win-win" strategy that addresses the needs of both companies. Fosun Pharma, with its strong marketing and extensive sales network, can quickly fill revenue gaps by acquiring a promising drug that is nearing final approval. Meanwhile, Junshi Biosciences, a research-driven company, gains immediate financial resources to support the development of its pipeline. This deal exemplifies the commercialization model in China, where local pharmaceutical companies leverage their strong sales capabilities to penetrate the market and compete with multinational pharmaceutical companies. The industry is closely watching to see if this model will continue to be successful.
This deal, centered around Roconkibart, a new drug awaiting approval from the China National Medical Products Administration (NMPA), will accelerate the generational shift in China's autoimmune disease market by combining Fosun Pharma's strong local distribution network with Junshi Biosciences' development capabilities. In the short term, the upfront payment of 215 million yuan and potential milestone payments of up to 1.12 billion yuan secured by Junshi Biosciences will enhance the financial stability of its pipeline. In the medium to long term, Roconkibart is expected to establish itself as a distinct domestic alternative in China's IL-17A psoriasis treatment market, currently dominated by Novartis' Cosentyx and Eli Lilly's Taltz, and increase its market penetration. This licensing agreement, which secures an asset nearing approval in a market estimated at 15 billion yuan, serves as a standard model for biotech companies seeking to diversify risk and maximize returns. The data from the Phase 3 trial, which showed a PASI 100 achievement rate of 65% at week 52, is comparable to the commercial value of Akeso's approved drug, Gumokimab (68.9%).